Sep 27 |
Regeneron, Sanofi Get FDA OK for Dupixent to Treat COPD
|
Sep 27 |
Sanofi, Regeneron get additional Chinese approval for Dupixent
|
Sep 27 |
Regeneron And Sanofi Snag Their $6 Billion-Potential COPD Approval For Dupixent
|
Sep 27 |
Press Release: Dupixent approved in the US as the first-ever biologic medicine for patients with COPD
|
Sep 27 |
Dupixent® (dupilumab) Approved in the U.S. as the First-ever Biologic Medicine for Patients with COPD
|
Sep 27 |
Dupixent® (dupilumab) Approved in China as the First-ever Biologic Medicine for Patients with Chronic Obstructive Pulmonary Disease (COPD)
|
Sep 27 |
Press Release: Dupixent approved in China as the first-ever biologic medicine for patients with COPD
|
Sep 27 |
FDA, after delay, clears Regeneron and Sanofi drug for COPD
|
Sep 26 |
Are Investors Undervaluing Sanofi (SNY) Right Now?
|
Sep 26 |
Buy These 5 Big Drug Stocks to Boost Your Portfolio's Health
|